 Poliovirus Vaccine, Oral
"Poliovirus Vaccine, Oral" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A live vaccine containing attenuated poliovirus, types I, II, and III, grown in monkey kidney cell tissue culture, used for routine immunization of children against polio. This vaccine induces long-lasting intestinal and humoral immunity. Killed vaccine induces only humoral immunity. Oral poliovirus vaccine should not be administered to immunocompromised individuals or their household contacts. (Dorland, 28th ed)
| Descriptor ID |
D011055
|
| MeSH Number(s) |
D20.215.894.899.623.750
|
| Concept/Terms |
Poliovirus Vaccine, Oral- Poliovirus Vaccine, Oral
- Oral Poliovirus Vaccine
- Vaccine, Oral Poliovirus
- Sabin Vaccine
- Vaccine, Sabin
|
Below are MeSH descriptors whose meaning is more general than "Poliovirus Vaccine, Oral".
Below are MeSH descriptors whose meaning is more specific than "Poliovirus Vaccine, Oral".
This graph shows the total number of publications written about "Poliovirus Vaccine, Oral" by people in this website by year, and whether "Poliovirus Vaccine, Oral" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 | | 2001 | 1 | 0 | 1 | | 2004 | 1 | 1 | 2 | | 2007 | 1 | 0 | 1 | | 2015 | 1 | 0 | 1 | | 2016 | 1 | 0 | 1 | | 2017 | 2 | 1 | 3 | | 2018 | 3 | 0 | 3 | | 2020 | 0 | 1 | 1 | | 2021 | 1 | 0 | 1 | | 2022 | 0 | 2 | 2 | | 2025 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Poliovirus Vaccine, Oral" by people in Profiles.
-
Godin A, Brickley EB, Connor RI, Wieland-Alter WF, Ackerman ME, Weiner JA, Modlin J, Arita M, Bandyopadhyay AS, Gast C, S?ez-Llorens X, R?ttimann RW, Van Damme P, De Coster I, Wright PF. Intestinal mucosal immune responses induced by novel oral poliovirus vaccine type 2 and Sabin monovalent oral poliovirus vaccine type 2: an analysis of data from four clinical trials. Lancet Microbe. 2025 Jun; 6(6):101028.
-
Brickley EB, Connor RI, Wieland-Alter W, Weiner JA, Ackerman ME, Arita M, Gast C, De Coster I, Van Damme P, Bandyopadhyay AS, Wright PF. Intestinal Antibody Responses to 2 Novel Live Attenuated Type 2 Oral Poliovirus Vaccines in Healthy Adults in Belgium. J Infect Dis. 2022 08 24; 226(2):287-291.
-
Franco-Paredes C, Rodriguez-Morales AJ, Henao-Mart?nez AF, Carrasco P, Tuells J. The growing threat of wild poliovirus 1 and vaccine-derived cases in the COVID-19 era. Lancet Infect Dis. 2022 10; 22(10):1412-1414.
-
Bandyopadhyay AS, Gast C, Brickley EB, R?ttimann R, Clemens R, Oberste MS, Weldon WC, Ackerman ME, Connor RI, Wieland-Alter WF, Wright P, Usonis V. A Randomized Phase 4 Study of Immunogenicity and Safety After Monovalent Oral Type 2 Sabin Poliovirus Vaccine Challenge in Children Vaccinated with Inactivated Poliovirus Vaccine in Lithuania. J Infect Dis. 2021 01 04; 223(1):119-127.
-
Franco-Paredes C, Santos-Preciado JI, Henao-Martinez AF, Rodriguez-Morales AJ, Carrasco P. Preventing paralytic polio caused by vaccine-derived poliovirus type 2. Lancet Infect Dis. 2020 01; 20(1):21-22.
-
Brickley EB, Wieland-Alter W, Connor RI, Ackerman ME, Boesch AW, Arita M, Weldon WC, O'Ryan MG, Bandyopadhyay AS, Wright PF. Intestinal Immunity to Poliovirus Following Sequential Trivalent Inactivated Polio Vaccine/Bivalent Oral Polio Vaccine and Trivalent Inactivated Polio Vaccine-only Immunization Schedules: Analysis of an Open-label, Randomized, Controlled Trial in Chilean Infants. Clin Infect Dis. 2018 10 30; 67(suppl_1):S42-S50.
-
Gaensbauer JT, Gast C, Bandyopadhyay AS, O'Ryan M, Saez-Llorens X, Rivera L, Lopez-Medina E, Melgar M, Weldon WC, Oberste MS, R?ttimann R, Clemens R, Asturias EJ. Impact of Maternal Antibody on the Immunogenicity of Inactivated Polio Vaccine in Infants Immunized With Bivalent Oral Polio Vaccine: Implications for the Polio Eradication Endgame. Clin Infect Dis. 2018 10 30; 67(suppl_1):S57-S65.
-
Brickley EB, Strauch CB, Wieland-Alter WF, Connor RI, Lin S, Weiner JA, Ackerman ME, Arita M, Oberste MS, Weldon WC, S?ez-Llorens X, Bandyopadhyay AS, Wright PF. Intestinal Immune Responses to Type 2 Oral Polio Vaccine (OPV) Challenge in Infants Previously Immunized With Bivalent OPV and Either High-Dose or Standard Inactivated Polio Vaccine. J Infect Dis. 2018 01 17; 217(3):371-380.
-
Bandyopadhyay AS, Asturias EJ, O'Ryan M, Oberste MS, Weldon W, Clemens R, R?ttimann R, Modlin JF, Gast C. Exploring the relationship between polio type 2 serum neutralizing antibodies and intestinal immunity using data from two randomized controlled trials of new bOPV-IPV immunization schedules. Vaccine. 2017 12 19; 35(52):7283-7291.
-
Brickley EB, Wright PF. Maximising the impact of inactivated polio vaccines. Lancet Infect Dis. 2017 07; 17(7):680-681.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|